Sorrento Therapeutics Inc logo

Sorrento Therapeutics Inc Share Price Today (NASDAQ: SRNE)

Sorrento Therapeutics Inc share price is $0 & ₹0.00 as on 20 Feb 2023 IST

Market is closed - opens 7 PM, 15 Jul 2025

Bell Icon

The stock has been delisted from the stock exchange on 21 Feb 2023

View live Sorrento Therapeutics Inc share price in Dollar and Rupees. Guide to invest in Sorrento Therapeutics Inc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Sorrento Therapeutics Inc, along with analyst recommendations, forecasts, and comprehensive financials.

Sorrento Therapeutics Inc (SRNE) Key Statistics

in dollars & INR

Previous Close
$0.0024
Open
$9.0E-4
Market Capitalization
$169.8M
Today's Volume
$92.1K
Revenue TTM
$60.3M
EBITDA
$-390.9M
Earnings Per Share (EPS)
$-1.53
Dividend Yield
0.0%
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-378.92%

How to invest in Sorrento Therapeutics Inc Stock (SRNE) from India?

It is very easy for Indian residents to invest directly in Sorrento Therapeutics Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Sorrento Therapeutics Inc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Sorrento Therapeutics Inc or SRNE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Sorrento Therapeutics Inc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Sorrento Therapeutics Inc shares which would translate to null fractional shares of Sorrento Therapeutics Inc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Sorrento Therapeutics Inc, in just a few clicks!

Global Institutional Holdings in Sorrento Therapeutics Inc

  • State Street Corporation

    7.42%

  • BlackRock Inc

    6.24%

  • Vanguard Group Inc

    5.39%

  • Geode Capital Management, LLC

    1.30%

  • D. E. Shaw & Co LP

    0.92%

  • Northern Trust Corp

    0.63%

Analyst Recommendation on Sorrento Therapeutics Inc

Rating
Trend

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Sorrento Therapeutics Inc(by analysts ranked 0 to 5 stars)

About Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc.
Organization
Sorrento Therapeutics Inc
Employees
799
CEO
Dr. Henry H. Ji Ph.D.
Industry
Health Technology

Important FAQs about investing in SRNE Stock from India :

Can Indians buy Sorrento Therapeutics Inc shares?

Yes, Indians can invest in the Sorrento Therapeutics Inc (SRNE) from India.

With INDmoney, you can buy Sorrento Therapeutics Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Sorrento Therapeutics Inc at zero transaction cost.

How can I buy Sorrento Therapeutics Inc shares from India?

It is very easy to buy Sorrento Therapeutics Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Sorrento Therapeutics Inc (SRNE) be purchased?

Yes, you can buy fractional shares of Sorrento Therapeutics Inc with INDmoney app.

What are the documents required to start investing in Sorrento Therapeutics Inc stocks?

To start investing in Sorrento Therapeutics Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Sorrento Therapeutics Inc?

Today's market capitalisation of Sorrento Therapeutics Inc SRNE is 169.8M

Who is the Chief Executive Officer (CEO) of Sorrento Therapeutics Inc ?

Dr. Henry H. Ji Ph.D. is the current Chief Executive Officer (CEO) of Sorrento Therapeutics Inc.